NCT00930319

Effectiveness and Safety of Firmagon®

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 676 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Other clinical parameters, the patients' quality of life and the direct and indirect costs incurred by the medical care for the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In this context the medical outcome and the life quality are defined as effectiveness and benefit value parameters. Both the effectiveness under daily life circumstances and economic variables of the therapy can thus be shown and compared within an analysis of costs vs. benefits or costs vs. effectiveness.

Conditions

• Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma

Interventions

Type	Name	Description
OTHER	Firmagon given by prescription according to SPC	Non-interventional,observational Firmagon given by prescription according to SPC

Timeline

• Start date: 2009-06-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2009-06-30
• Last updated: 2023-11-09

Locations

230 sites across 1 country: Germany